Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 29:20:467.
doi: 10.1186/s12935-020-01518-y. eCollection 2020.

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Chao Xue  1 , Xin Wang  1   2   3 , Lingyan Zhang  3 , Qingyuan Qu  1 , Qian Zhang  3 , Yujie Jiang  3
Affiliations
Review

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Chao Xue et al. Cancer Cell Int. .

Abstract

Background: In recent years, the B cell receptor (BCR) signaling pathway has become a "hot point" because it plays a critical role in B-cell proliferation and function. Bruton's tyrosine kinase (BTK) is overexpressed in many subtypes of B-cell lymphoma as a downstream kinase in the BCR signaling pathway. Ibrutinib, the first generation of BTK inhibitor, has shown excellent antitumor activity in both indolent and aggressive B-cell lymphoma.

Main body: Ibrutinib monotherapy has been confirmed to be effective with a high response rate (RR) and well-tolerated in many B-cell lymphoma subgroups. To achieve much deeper and faster remission, combination strategies contained ibrutinib were conducted to evaluate their synergistic anti-tumor effect.

Conclusions: For patients with indolent B-cell lymphoma, most of them respond well with ibrutinib monotherapy. Combination strategies contained ibrutinib might be a better choice to achieve deeper and faster remission in the treatment of aggressive subtypes of B-cell lymphoma. Further investigations on the long-term efficacy and safety of the ibrutinib will provide novel strategies for individualized treatment of B-cell lymphoma.

Keywords: B cell receptor (BCR) signaling pathway; B-cell lymphoma; Bruton’s tyrosine kinase (BTK); Ibrutinib; Monotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Structure of Bruton’s tyrosine kinase (BTK) and associated cross-linking signaling pathways. a BTK comprises five structural domains. BTK activation occurs twice during phosphorylation upon the plasma membrane. The first phosphorylation occurs on the Tyr551 site within the kinase domain by the Syk or Src family kinase, which subsequently leads to autophosphorylation of Tyr223 in the SH3 domain, achieving full activation of BTK kinase activity. b BTK activation process and inhibited result of cross-linking pathways by BTK inhibitors. The left figure shows when extracellular antigen bond BCR, BTK can regulate adverse cellular biological processes by activating multiple important pathways, such as NF-kB, MAPK, NFAT, and mTOR pathway. The right figure shows when the BCR pathway is irreversibly inhibited by small-molecule BTK inhibitors, its downstream pathway such as NF-kB, MAPK, and NFAT will also be inhibited, resulting in anti-tumor activity in B cell lymphoma
See this image and copyright information in PMC

References

    1. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018;182(4):504–12. doi: 10.1111/bjh.15421. - DOI - PMC - PubMed
    1. Jerkeman M, Eskelund CW, Hutchings M, Raty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109-e16. doi: 10.1016/S2352-3026(18)30018-8. - DOI - PubMed
    1. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. doi: 10.1056/NEJMoa1509388. - DOI - PMC - PubMed
    1. Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, et al. p53-independent ibrutinib responses in an Emu-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J. 2016;6:e434. doi: 10.1038/bcj.2016.41. - DOI - PMC - PubMed
    1. Jain N. Selecting frontline therapy for CLL in 2018. Hematology Am Soc Hematol Educ Program. 2018;2018(1):242–7. doi: 10.1182/asheducation-2018.1.242. - DOI - PMC - PubMed

LinkOut - more resources